- Grifols (GRFS -4.2%) forecasts new product sales to make up about one fifth of the company's total revenue by 2030.
- The company, in its investor presentation slides as part of its analyst day, forecast revenue from new product launches to grow to 20% of its total topline by 2030, up from about 4% in 2020.
- The company also highlighted that it intends to focus on therapeutic areas, and expects to progressively incorporate non-plasma assets to balance its portfolio.
- The company's shares have lost nearly 5% of their value YTD.
- Seeking Alpha contributor Stanislas Capital recently opined that the plasma-supply disruption provides an attractive entry point for the company, and highlighted that Grifols operates in the very attractive and lucrative plasma business.
- Grifols started commercializing HyperHEP B, a new formulation of its hepatitis B immune globulin for hepatitis B postexposure prophylaxis, earlier this week.